trial

Imagery Rescripting as a Treatment for Early Psychosis

NCTId NCT06539780
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Active Not Recruiting
Enrollment 8 (estimated)
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Primary completion 2025-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Active Not Recruiting
Enrollment
8 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2024-12-20
Primary completion
2025-12
Eligibility
ALL · 16 Years · 45 Years

Interventions & indications

Drugs
Imagery Rescripting

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Lead Sponsor

Investigators

2
Damiaan Denys, ProfPrincipal Investigator
Arnoud Arntz, Prof.Principal Investigator

Sites

1 total
Amsterdam-Zuidoost, Netherlands

Facts & assertions

4 sourced
Enrollment
8
Phase
NA
Primary Completion Date
2025-12
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
Imagery Rescripting
drug
lead_sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
company
indication
Psychotic Disorders
indication
Psychosis
indication
Psychotic Disorders
indication
investigator
Damiaan Denys, Prof
person
Arnoud Arntz, Prof.
person